<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553786</url>
  </required_header>
  <id_info>
    <org_study_id>REVAIL</org_study_id>
    <nct_id>NCT01553786</nct_id>
  </id_info>
  <brief_title>Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)</brief_title>
  <official_title>STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of lenalidomide associated with CHOP as measured by
      complete response rate at the end of treatment. Approximately 80 patients aged between 60 and
      80 years will be included, to have 70 evaluable patients. The treatment consists of two
      phases of four 3-weeks cycles: induction phase and consolidation phase, for a total treatment
      duration of 24 weeks. Each cycle will be broken down as follows: chemotherapy will be
      administered in the hospital on day 1, prednisone is continued for 5 days and lenalidomide is
      taken for 14 days. Patients will be followed for at least 18 months after inclusion of the
      last patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>maximum 60 days after last study drug intake</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lenalidomide + CHOP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide</description>
    <arm_group_label>lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven T-cell angioimmunoblastic lymphoma (AITL)

          -  Age from 60 to 80 years.

          -  Eastern Cooperative Oncology Group performance status 0 to 2.

          -  No previous therapy (except corticosteroids providing they have been initiated less
             than 15 days before inclusion).

          -  Spontaneous life expectancy &gt; 1 month.

          -  Written informed consent. The Lenalidomide Information Sheet (in appendix N of the
             protocol) will be given to each patient receiving lenalidomide study therapy. The
             patient must read this document prior to starting lenalidomide study treatment and
             each time they receive a new supply of study drug.

          -  Male patients must:

               -  Agree to use a condom during sexual contact with a FCBP, even if they have had a
                  vasectomy, throughout study drug therapy, during any dose interruption and after
                  cessation of study therapy.

               -  Agree to not give semen or sperm during study drug therapy and for a period after
                  end of study drug therapy.

          -  All patients must:

               -  Have an understanding that the study drug could have a potential teratogenicity.

               -  Agree to abstain from donating blood while taking study drug therapy and
                  following discontinuation of study drug therapy.

               -  Agree not to share study medication with another person.

               -  Be counselled about pregnancy precautions and risks of foetal exposure.

        Exclusion Criteria:

          -  Others categories of T-cell lymphoma.

          -  Central nervous system involvement by lymphoma.

          -  Any previous therapy for lymphoma except short-term corticosteroids (maximum 10 days)
             before inclusion.

          -  Contra-indication to any drug included in the CHOP regimen.

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study (according to the investigator's decision).

          -  Active bacterial, viral or fungal infection, in particular active hepatitis B or C and
             HIV positive serological test.

          -  Impaired renal function (Creatinine clearance &lt;50 ml/min (as calculated by the
             Cockcroft-Gault formula)) or impaired liver function tests (total bilirubin level &gt; 30
             µmol/L, transaminases &gt; 2.5 upper normal limits) unless they are related to the
             lymphoma.

          -  Poor bone marrow reserve as defined by neutrophils &lt; 1.0 x 109/L or platelets &lt; 100 x
             109/L, unless related to bone marrow infiltration.

          -  Any history of malignancy, other than that treated in this research, unless the
             patient has remained free of the disease for over 5 years.

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Hypersensitivity to the active substance or to any of the excipients.

          -  Pregnant and lactating woman

          -  Females of Childbearing potential (FCBP*) according to the Pregnancy Prevention Plan
             in appendix L of the protocol)

               -  The Pregnancy Prevention Plan defines a female of childbearing potential as a
                  sexually mature woman who: 1) has not undergone a hysterectomy or bilateral
                  oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following
                  cancer therapy does not rule out childbearing potential) for at least 24
                  consecutive months (i.e., has had menses at any time in the preceding 24
                  consecutive months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne HAIOUN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvain ROBREAU</last_name>
    <phone>0033 4 72 66 93 33</phone>
    <email>yvain.robreau@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Université Catholique de Louvain Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric VAN DEN NESTE</last_name>
      <phone>0032 27 64 18 75</phone>
      <email>eric.vandenneste@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Eric VAN DEN NESTE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fritz OFFNER</last_name>
      <phone>0032 93 32 21 32</phone>
      <email>fritz.offner@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Fritz OFFNER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Université Catholique de Louvain Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc ANDRE</last_name>
      <phone>00 32 81 42 38 64</phone>
      <email>marc.andre@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Marc ANDRE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre MAROLLEAU</last_name>
      <phone>0033 322455914</phone>
      <email>marolleau.jean-pierre@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre MAROLLEAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre MOLES-MOREAU</last_name>
      <email>mpmoles@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre MOLES-MOREAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon - Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hacène ZERAZHI</last_name>
      <phone>0033 4 32 75 32 51</phone>
      <email>hzerazhi@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Hacène ZERAZHI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric DECONINCK</last_name>
      <phone>0033 3 81 66 82 32</phone>
      <email>edeconinck@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric DECONINCK, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna SCHMITT</last_name>
      <phone>0033 5 56 33 32 67</phone>
      <email>schmitt_a@bergonie.org</email>
    </contact>
    <investigator>
      <last_name>Anna SCHMITT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier FITOUSSI</last_name>
      <phone>0033 5 56 43 73 54</phone>
      <email>o.fitoussi@bordeauxnord.com</email>
    </contact>
    <investigator>
      <last_name>Olivier FITOUSSI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Chalon sur Saone William Morey</name>
      <address>
        <city>Châlon sur saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent VOILLAT</last_name>
      <phone>0033 3 85 44 66 98</phone>
      <email>laurent.voillat@ch-chalon71.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent VOILLAT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria CACHEUX</last_name>
      <phone>0033 4 73 75 00 65</phone>
      <email>vcacheux@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Victoria CACHEUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien de Corbeil</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand JOLY</last_name>
      <phone>0033 1 60 90 31 46</phone>
      <email>bertrand.joly@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand JOLY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN</last_name>
      <phone>0033 1 49 81 41 54</phone>
      <email>corinne.haioun@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne HAIOUN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS</last_name>
      <phone>0033 3 80 29 50 47</phone>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CASASNOVAS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remy GRESSION</last_name>
      <phone>0033 4 76 76 59 53</phone>
      <email>rgressin@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Rémy GRESSIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Départemental</name>
      <address>
        <city>La roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé MAISONNEUVE</last_name>
      <phone>0033 2 51 44 61 61</phone>
      <email>herve.maisonneuve@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé MAISONNEUVE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER</last_name>
      <phone>0033 3 20 44 60 68</phone>
      <email>f-morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Réda BOUABDALLAH</last_name>
      <phone>0033 4 91 22 33 33</phone>
      <email>bouabdallahr@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Réda BOUABDALLAH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wajed ABARAH - ATASI</last_name>
      <phone>0033 1 64 35 38 75</phone>
      <email>w-abarah@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Wajed ABARAH - ATASI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON</last_name>
      <phone>0033 4 67 33 83 62</phone>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume CARTRON, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven LE GOUILL</last_name>
      <phone>0033 2 40 08 32 71</phone>
      <email>steven.legouill@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Steven LE GOUILL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine THIEBLEMONT</last_name>
      <phone>0033 1 42 49 98 37</phone>
      <email>catherine.thieblemont@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine THIEBLEMONT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard DELARUE</last_name>
      <phone>0033 1 44 49 52 97</phone>
      <email>richard.delarue@nck.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Richard DELARUE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal BOUABDALLAH</last_name>
      <phone>0033 5 57 65 65 11</phone>
      <email>kamal.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Kamal BOUABDALLAH, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand COIFFIER</last_name>
      <email>bertrand.coiffier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand COIFFIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Région d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette CORRONT</last_name>
      <phone>0033 4 50 63 66 08</phone>
      <email>bcorront@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Bernadette CORRONT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain DELMER</last_name>
      <phone>0033 3 26 78 36 44</phone>
      <email>adelmer@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Alain DELMER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LAMY</last_name>
      <phone>0033 2 99 28 42 92</phone>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry LAMY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé TILLY</last_name>
      <phone>0033 2 32 08 22 02</phone>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé TILLY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FEUGIER</last_name>
      <phone>0033 3 83 15 32 82</phone>
      <email>p.feugier@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FEUGIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-cell lymphoma</keyword>
  <keyword>CHOp</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

